← All trials
NCT04546581
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 8, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Jul 31, 2021
- First posted
- Sep 14, 2020
- Last posted
- Dec 9, 2020
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MinnesotaLead sponsor
- University of New South WalesStudy chair
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Institutes of Health (NIH)Collaborator
- University of MinnesotaOverall official - principal investigator
- The International Network for Strategic Initiatives in Global HIV TrialsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.